JNJ Johnson & Johnson

131.36
+0.82  (+1%)
Previous Close 130.54
Open 131.47
Price To Book 5.7
Market Cap 346,680,783,627
Shares 2,639,165,527
Volume 5,858,863
Short Ratio 2.18
Av. Daily Volume 7,305,784

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 initiation announced October 31, 2017.
DARZALEX (Daratumumab) using ENHANZE
Amyloidosis
Phase 3 discontinuation announced October 17, 2017.
Talacotuzumab
Acute myeloid leukemia (AML)
Approval announced February 14, 2018.
Apalutamide
Non-metastatic castration-resistant prostate cancer (CRPC)
FDA Approval announced July 17, 2018.
D/C/F/TAF
HIV
Approval announced August 2, 2017.
Imbruvica
Second-line Chronic graft-versus-host disease (GVHD)
Approval announced October 30, 2017. sNDA flled December 14, 2018. Estimated PDUFA date October 13, 2019.
XARELTO (rivaroxaban)
Reduce the Risk of Recurrent Venous Thromboembolism (VTE)
Phase 3 trial stopped early due to positive efficacy - February 8, 2017.
XARELTO (rivaroxaban)
Coronary Artery Disease or Peripheral Artery Disease
FDA Approval announced October 30, 2018.
INVOKANA CANVAS
Type 2 diabetes
sNDA filing announced March 28, 2019. Priority review announced May 22, 2019. Estimated PDUFA date September 27, 2019.
INVOKANA - CREDENCE
Diabetic Kidney Disease
Approval announced May 7, 2018.
DARZALEX (Daratumumab) - ALCYONE
Frontline multiple myeloma (non-transplant)
FDA approval announced March 5, 2019.
Esketamine
Treatment resistant depression
sNDA filing announced September 26, 2017. Priority Review. Approved January 19, 2017.
Imbruvica
Marginal zone lymphoma
Approval announced October 13, 2017.
STELARA (USTEKINUMAB)
Plaque psoriasis
Approval announced October 20, 2017.
SIMPONI ARIA
Psoriatic arthritis (PsA)
Approval announced October 20, 2017.
SIMPONI ARIA
Ankylosing Spondylitis
Approval announced July 13, 2017.
Guselkumab
Plaque psoriasis
CRL issued September 22, 2017. Advisory Committee Meeting August 2, 2017 voted 12-1 against that safety data is adequate to support approval. 13-0 in favor of efficacy.
Sirukumab
Rheumatoid arthritis
Approval announced June 16, 2017 - note: submitted by Janssen Biotech, Inc.
DARZALEX (Daratumumab) + pomalidomide and dexamethasone
Relapsed or refractory multiple myeloma
sNDA approval announced February 8, 2018.
ZYTIGA (abiraterone acetate) - LATITUDE
metastatic hormone-naïve prostate cancer (mHNPC)
FDA Approval announced April 12, 2019.
Erdafitinib
Urothelial cancer
NDA filing announced April 29, 2019. Estimated PDUFA date April 28, 2020.
Dolutegravir + rilpivirine
Injectable 2DR in HIV
Announced May 18, 2018 that dosing will be stopped.
Atabecestat
Alzheimer’s disease
FDA approval announced August 27, 2018.
IMBRUVICA (ibrutinib)
Waldenström’s Macroglobulinemia
Phase 2/3 trial initiation announced July 11, 2018.
Guselkumab (GALAXI 1)
Crohn's disease
Phase 3 trial did not meet primary endpoint - noted July 11, 2018.
IMBRUVICA (ibrutinib)
Diffuse large B-cell lymphoma (DLBCL)
Phase 2 trial initiation announced November 19, 2018.
Guselkumab (NOVA)
Hidradenitis Suppurativa
FDA Approval announced June 28, 2019.
Daratumumab - MAIA
Newly Diagnosed Multiple Myeloma (NDMM)
Phase 3 primary endpoint met - December 12, 2018.
Guselkumab vs Cosentyx - ECLIPSE
Psoriasis
sBLA filing announced July 12, 2019. PDUFA estimate May 12, 2020.
DARZALEX (Daratumumab) using ENHANZE
Multiple myeloma
Phase 2a initiation announced January 17, 2019.
Guselkumab
Ulcerative colitis
sBLA filed December 20, 2018. Estimated PDUFA date December 19, 2019.
STELARA (USTEKINUMAB)
Ulcerative colitis
sNDA filing announced April 29, 2019. Estimated PDUFA date February 28, 2020.
Apalutamide
Metastatic castration-sensitive prostate cancer (mCSPC).
Phase 2 initial data to be presented at ASCO GU February 14, 2019. ORR 40%.
Niraparib (Galahad)
Castration-Resistant Prostate Cancer
Approval announced February 27, 2019.
Guselkumab
Plaque psoriasis
PDUFA date September 26, 2019.
Daratumumab + VTD
Multiple myeloma - candidates for autologous stem cell transplant (ASCT)
Phase 3 trial met primary endpoint.
Ponesimod
Relapsing multiple sclerosis

Latest News

  1. Top Defensive Consumer Stocks for 2018
  2. JOHNSON & JOHNSON INVESTIGATION UPDATE by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Johnson & Johnson - JNJ
  3. Jabil Inc. -- Moody's assigns Prime-3 short term rating to Jabil's new $1.8 billion commercial paper program
  4. Pharma Stock Roundup: Pipeline/Regulatory Updates From JNJ, LLY, AZN, RHHBY
  5. 10 Best Stocks to Buy and Hold Forever
  6. The Top Pharma Stocks for 2019
  7. Why Is Johnson & Johnson (JNJ) Down 1.2% Since Last Earnings Report?
  8. Lilly's Taltz Outshines J&J's Tremfya in Psoriasis Study
  9. JNJ Stock Is a Way Better Investment Than Bonds or CDs
  10. Lilly's Psoriasis Drug Found Superior To J&J's Tremfya In Phase 4 Study
  11. What Kind Of Shareholders Own Johnson & Johnson (NYSE:JNJ)?
  12. 5 Biggest New Drugs Approved in 2019 So Far
  13. Dow Jones Falls 300 Points; Pfizer, Goldman Sachs Lead Downside
  14. The 10 Biggest Value Stocks
  15. J&J's Tuberculosis Drug Gets FDA Nod for Adolescent Patients
  16. Why Johnson & Johnson (JNJ) is a Top Dividend Stock for Your Portfolio
  17. 3 Top Dividend Aristocrats to Buy Now
  18. Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates
  19. Johnson & Johnson Is A Massive Pharma Stock — But Should You Buy It?
  20. Johnson & Johnson to Participate in Barclays Global Consumer Staples Conference